
|Videos|October 18, 2013
Ipilimumab in the Adjuvant Setting for Melanoma
Author(s)Vernon K. Sondak, MD
Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.
Advertisement
Clinical Pearls
Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.
- There are a number of studies looking at ipilimumab in the adjuvant setting
- There has been a fair amount of toxicity associated with the 10-mg/kg dosage
- Adjuvant therapy with ipilimumab outside of a clinical trial is not recommended
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Varegacestat Achieves PFS Gains, Deep Shrinkage of Desmoid Tumors
3
Deep Proteomic, AI Breast Cancer Detection Test Demonstrates High Performance
4
Erdafitinib Demonstrates Manageable Toxicity, Early Efficacy in Glioma
5










































